Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770105 | 0.85 | APP (0.56) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL772566 | 0.83 | MAPT (0.78) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL74009 | 0.82 | FLT3 (0.65) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL785572 | 0.81 | APP (0.58) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL74324 | 0.81 | APP (0.56) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL1853165 | 0.79 | APP (0.77) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL796947 | 0.78 | APP (0.76) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL31338680 | 0.78 | MAPT (0.66) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL10067623 | 0.77 | APP (0.86) | APPTP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL796966 | 0.77 | APP (0.83) | APPTP53MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| EP-2358725-A1 | Imidazolothiazole compounds as modulators of protein kinase | Ambit Biosciences Corporation (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GRK2, GRK3, GRK4 | APP 4143/4885TP53 905/4885MAPT 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.